• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vaxxim - Articles and news items


First patient treated in Phase I VXM01 glioblastoma trial

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Vaximm’s VXM01 is a oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +